Under construction – not a live service
Sign in
Taking people in CanadaNo phase

Acoustic OSA Prediction During Wakefulness and Monitoring During Sleep

Key facts

Where
Winnipeg, CanadaSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Source: NCT04112927, who can take part

Where in Canada

  • University of ManitobaWinnipeg, CanadaContact: Abnoor Kaur, M.Sc.Taking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
University of Manitoba
Trial code
NCT04112927
Record updated
30 September 2026
Original description
The purpose of this study is to investigate the feasibility of sound analysis for: a) sleep apnea detection both during wakefulness and sleep, and b) flow-sound relationship during both wakefulness and sleep in patients and control individuals. The ultimate goal of our research is to simplify the current assessments for sleep apnea detection so that it is more convenient for patients and also much faster than the current techniques.Read full original descriptionShow less

The purpose of this study is to investigate the feasibility of sound analysis for: a) sleep apnea detection both during wakefulness and sleep, and b) flow-sound relationship during both wakefulness and sleep in patients and control individuals. The ultimate goal of our research is to simplify the current assessments for sleep apnea detection so that it is more convenient for patients and also much faster than the current techniques.

Inclusion: 1) age between 18 to 70 years; 2) suspected of OSA and referred to full PSG study by a doctor.

Exclusion: 3) drug addiction; 1) being diagnosed with a chronic respiratory disease including pulmonary fibrosis, emphysema, respiratory infectious disease, nocturnal asthma, obstructive pulmonary lung disease, pulmonary hypertension, congestive heart failure, sleep related hypoventilation and neuromuscular disorders; 2) having insomnia or restless leg; 4) under the current, direct supervision of the PI of this study.

ClinicalTrials.gov NCT04112927